Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nipro Pharma Submits Business Improvement Plan after GMP Issues
June 1, 2023
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- Braftovi/Mektovi Filed for Thyroid Cancer in Japan: Ono
June 1, 2023
- Maruho’s Bepio Lotion Hits Japan Pharmacy Shelves
June 1, 2023
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
- Seikagaku Nets Positive Data in Additional US PIII for Herniated Disk Drug
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- PharmaEssentia’s 1st Product to Hit Japan Market on June 1
May 29, 2023
- Ex-Takeda Exec Motoi Muraki to Take Helm at ViiV Japan
May 26, 2023
- Astellas to Transfer Manufacturing Plant in Netherlands to French Firm
May 26, 2023
- Clinical Trial Notification Filed for RPE Tear Cell Therapy: Sumitomo/Healios
May 26, 2023
- GSK’s Pediatric Antibiotic Clavamox to Be Out of Stock on Demand Spike
May 25, 2023
- Some 400 General Employees Likely Leaving Bayer under Redundancy Program
May 25, 2023
- Lilly’s Omvoh Launch Set for June 21; BioMarin’s Palynziq Now Available
May 25, 2023
- Novartis Japan Rolling Out New Operational Model Tailored to Local Needs: President
May 24, 2023
- Mitsubishi Tanabe to Refine Growth Scenario, Expand Overseas Operations under New Leadership
May 24, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…